BioSpace News Archive

Business

Compugen Reports Third Quarter 2022 Results

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, provided a corporate update and announced financial results for the third quarter ended September 30, 2022.

November 14, 2022
·
9 min read
Business

Arbe Announces Q3 2022 Financial Results

Arbe Robotics Ltd., a global leader in next-generation 4D Imaging Radar Solutions, announced financial results for its third quarter ended September 30, 2022.

November 14, 2022
·
14 min read
Bio NC

RedHill Accelerates Opaganib’s Nuclear Radiation Protection Program - Positive Data Published

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced acceleration of opaganib’s development program for protection against radiation injury and cancer radiotherapy.

November 14, 2022
·
19 min read
Business

Leap Therapeutics Reports Third Quarter 2022 Financial Results

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2022.

November 14, 2022
·
11 min read
Pharm Country

CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled

CytoSorbents Corporation (NASDAQ: CTSO) announced that 40 of the targeted 120 patients have been enrolled in the Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) trial, achieving the first enrollment milestone and triggering a pre-specified Data and Safety Monitoring Board (DSMB) review.

November 14, 2022
·
7 min read
Business

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the quarter ended September 30, 2022.

November 14, 2022
·
9 min read
Business

Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

Zynerba Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2022, and provided an overview of recent operational highlights and a pipeline update.

November 14, 2022
·
11 min read
Pharm Country

Curavit Raises $5 Million in Series A Funding to Accelerate Growth in Digital Therapeutics Clinical Research

Curavit Clinical Research today announced it raised $5 million in Series A funding to accelerate its growing portfolio of research in the global digital therapeutics (DTx) market (projected to grow at a CAGR of 31.4% through 2026).

November 14, 2022
·
4 min read
Business

Alimera Sciences Announces Third Quarter 2022 Financial Results

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the third quarter of 2022.

November 14, 2022
·
13 min read
Business

Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal first quarter ended September 30, 2022.

November 14, 2022
·
14 min read